Hemoglobin modification

Blood Substitutes

Volumn , Issue , 2006, Pages 341-353

  Winslow, Robert M ^a,b  

^a SANGART INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58849135395     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012759760-7/50040-8     Document Type: Chapter

References (105)

1. Acharya A., Manjula B., Smith P. Hemoglobin Crosslinkers, Patent No. 5,585,484 1996, Albert Einstein College of Medicine of Yeshiva University.
2. Adamson J.G., Bonaventura B.J., Song S.E., et al. Production, characterization, and clinical evaluation of Hemolink, an oxidized raffinose crosslinked hemoglobin-based blood substitute. Red Blood Cell Substitutes 1998, 335-351. Marcel Dekker, New York. A.S. Rudolph, R. Rabinovici, G.Z. Feuerstein (Eds.).
3. 2 and/or inositolhexaphosphate (IHP). Trans. Am. Soc. Artif. Intern. Organs 1987, 33:372-373.
4. Ajisaka K., Iwashita Y. Modification of human hemoglobin with polyethylene glycol: a new candidate for blood substitute. Biochem. Biophys. Res. Comm. 1980, 97:1076-1081.
5. Amberson W. Blood substitutes. Biol. Rev. 1937, 12:48-86.
6. Arnone A., Benesch R., Benesch R. Structure of human deoxyhemoglobin specifically modified with pyridoxal compounds. J. Mol. Biol. 1977, 115:627-642.
7. Ayer G., Gauld A. Uremia following blood tranfusion. Arch. Pathol. 1942, 33:513-532.
8. Bakker J., Bleeker W., VanderPlas J. Properties of hemoglobin interdimerically crosslinked with NFPLP. Progr. Clin. Biol. Res. 1986, 211:49-55.
9. Barcroft J., Binger C., Bock A., et al. Observations upon the effect of high altitude on the physiological processes of the human body carried out in the Peruvian Andes chiefly at Cerro de Pasco. Philos. Trans. R. Soc. Lond. Ser. B 1923, 211:351-480.
10. Behringer R., Ryan T., Reilly M., et al. Synthesis of functional human hemoglobin in transgenic mice. Science 1989, 245:971-973.
11. Bellelli A., Brunori M. Hemoglobin solutions as blood substitutes: an overview. Ann. Ital. Med. Int. 1986, 1:275-280.
12. Benesch R., Benesch R. Preparation and properties of hemoglobin modified with derivatives of pyridoxal. Methods Enzymology 1981, 147-158. Academic Press, New York. 1976 edn. E. Antonini, L. Rossi-Bernardi, E. Chiancone (Eds.).
13. Benesch R., Kwong S. Bis-pyridoxal polyphosphates: a new class of specific intramolecular crosslinking agents for hemoglobin. Biochem. Biophys. Res. Comm. 1988, 156:9-14.
14. Benesch R., Benesch R., Yung S., Edalji R. Hemoglobin covalently bridges across the polyphosphate binding site. Biochem. Biophys. Res. Comm. 1975, 63:1123-1129.
15. Benesch R., Benesch R., Kwong S. Labeling of hemoglobin with pyridoxal phosphate. J. Biol. Chem. 1982, 257:1320-1324.
16. Benesch R., Triner L., Benesch R., et al. Enhanced oxygen unloading by an interdimerically crosslinked hemoglobin in an isolated perfused rabbit heart. Proc. Natl. Acad. Sci. USA 1984, 81:2941-2943.
17. Bleeker W., VanderPlas J., Feitsma R., et al. In vivo distribution and elimination of hemoglobin modified by intramolecular crosslinking with 2-nor-2-formylpuridoxal 5′-phosphate. J. Lab. Clin. Med. 1989, 113:151-161.
18. Bleeker W., VanderPlas J., Feitsma R., et al. Hemoglobin radiolabeling: in vitro and in vivo comparison of iodine labeling with iodogen and a new method for technetium labeling. Nucl. Med. Biol. 1989, 16(4):365-369.
19. Blumenstein J., Tam S., Chang J., Wong J. Experimental transfusion of dextranhemoglobin. Blood Substitutes and Expanders 1978, 205-212. Alan R. Liss, New York. G. Jamieson, T. Greenwalt (Eds.).
20. Brown G., Dale H. Perfusion with a solution of hemolyzed red corpuscles. J Physiol. 1936, 86:42P-43P.
21. Bucci E., Razynska A., Urbaitis B., Fronticelli C. Pseudo crosslink of human hemoglobin with mono-(3,5-dibromosalicy)fumarate. J. Biol. Chem. 1989, 264:6191-6195.
22. Bucci E., Fronticelli C., Razynska A., Urbaitis B. Overview of chemically obtained oxygen carriers from hemoglobin: pseudocrosslinked tetramers. Biomat. Artif. Cells Artif. Organs 1989, 17(5):637.
23. Bunn H. Differences in the interaction of 2,3-diphosphoglycerate with certain mammalian hemoglobins. Science 1971, 172:1049-1050.
24. Burhop K.E., Estep T.E. Hemoglobin-induced myocardial lesions. Artif. Cells Blood Subst. Immob. Biotech. 2001, 29(2):101.
25. Burhop K., Doyle M., Schick M., Matthews M. The development and preclinical testing of a novel second-generation recombinant hemoglobin solution. The 9th International Symposium on Blood Substitutes Program 2003, II:50. 1, (abstract).
26. Carmichael F.J., Ali A.C., Campbell J.A., et al. A phase I study of oxidized raffinose crosslinked human hemoglobin. Crit. Care Med. 2000, 28(7):2283-2292.
27. Carson J., Noveck H., Berlin J., Gould S. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002, 42:812-818.
28. Chang J., Wong J. Synthesis of soluble dextran-hemoglobin complexes of different molecular sizes. Can. J. Biochem. 1977, 55:398-403.
29. Christensen S., Medina F., Winslow R., et al. Preparation of human hemoglobin Ao for possible use as a blood substitute. J. Biochem. Biophys. Meth. 1988, 17:143-154.
30. Cunnington P.G., Jenkins S.N., Tam S.C., Wong J.T. Oxygen-binding and immunological properties of complexes between dextran and animal haemoglobins. Biochem. J. 1981, 193(1):261-266.
31. DeVenuto F. Evaluation of human and bovine modified-hemoglobin solution as oxygen-carrying fluid blood volume replacement. Biomat. Artif. Cells Artif. Organs. 1988, 16(1-3):77-83.
32. DeVenuto F., Zegna A. Transfusion with pyridoxalated-polymerized hemoglobin solutions. Transfusion 1981, 21:599.
33. DeVenuto F., Zegna A. Preparation and evaluation of pyridoxalated-polymerised human human haemoglobin. J. Surg. Res. 1983, 34:205-212.
34. DeVenuto F., Zuck T., Zegna A., Moores W. Characteristics of stroma-free hemoglobin prepared by crystallization. J. Lab. Clin. Med. 1977, 89:509-516.
35. Doherty D.H., Doyle M.P., Curry S.R., et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nature Biotechnol. 1998, 16:672-676.
36. Estep T., Bechtel M., Miller T., Bagdasarian A. Virus inactivation in hemoglobin solutions by heat. Artif. Cells Blood Subst. Immob. Biotech. 1988, 16(1-3):129-134.
37. Estep T., Bechtel M., Bush S., et al. The purification of hemoglobin solutions by heating. The Red Cell, Seventh Ann Arbor Conference 1989, 325-338. Alan R. Liss, New York. G. Brewer (Ed.).
38. Fantl W., Manning L., Ueno H., et al. Properties of carboxymethylated crosslinked hemoglobin A. Biochemistry 1987, 26:5755-5761.
39. Fantl W., Donato A., Manning J., et al. Specifically carboxymethylated hemoglobin as an analogue of carbamino hemoglobin. Solution and X-ray studies of carboxymethylated hemoglobin and X-ray studies of carbamino hemoglobin. J. Biol. Chem. 1987, 26:12700-12713.
40. Feola M., Gonzalez H., Canizaro P., et al. Development of a bovine stroma-free hemoglobin solution as a blood substitute. Surg. Gynecol. Obstet. 1983, 157:399-408.
41. Friedman H., DeVenuto F., Schwartz B., Nemeth T. In vivo evaluation of pyridoxalated-polymerized hemoglobin solution. Surgery 1984, 159:429-435.
42. Fronticelli C., Bucci E., Orth C. Solvent regulation of oxygen affinity in hemoglobin. J. Biol. Chem. 1984, 259:10841-10844.
43. Fronticelli C., Sato T., Orth C., Bucci E. Bovine hemoglobin as a potential source of hemoglobin-based oxygen carriers: crosslinking with bis(2,3-dibromosalycyl) fumarate. Biochem. Biophys. Acta 1986, 874:76-81.
44. Gendler E., Gendler S., Nimni M. Toxic reactions evoked by glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis. J. Biomed. Mater. Res. 1984, 18:727-736.
45. Gould S.A., Moore E.E., Hoyt D.B., Ness P.M., et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J. Am. Coll. Surg. 2002, 195(4):445-452. discussion, 452-455.
46. Gould S., Sehgal L., Rosen A., et al. The development of polymerized pyridoxylated hemoglobin solution a red cell substitute. Ann. Emerg. Med. 1986, 15:1416-1419.
47. Greenburg A., Maffuid P. Modification of hemoglobin-ring opened dials. Progress in Clinical and Biological Research: Advances in Blood Substitute Research 1983, 9-17. Alan R. Liss, New York. R. Bolin, R. Geyer, G. Nemo (Eds.).
48. Guillochon D., Vijayalakshmi M., Sow-Thiam A., Thomas D. Effect of glutaraldehyde on hemoglobin: functional aspects and mossbauer parameters. Biochemistry 1986, 64(1):29-37.
49. Hamilton P., Hiller A., Van Slyke D. Renal effects of hemoglobin infusions in dogs in hemorrhagic shock. J. Exper. Med. 1947, 86:477-487.
50. Hill S.E., Gottschalk L.I., Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. J. Cardiothorac. Vasc. Anesth. 2002, 16(6):695-702.
51. Hoffman S., Looker D., Roehrich J., et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc. Natl. Acad. Sci. USA 1990, 87:8521-8525.
52. Hoyt D., Greenburg A., Peskin G., et al. Hemorrhagic shock and resuscitation: improved survival with pyridoxalated stroma-free hemoglobin. Surg. Forum 1980, 31:15-17.
53. Humphries R., Killingback P., Mann J., et al. Exchange transfusion with dextran-hemoglobin, hemoglobin and dextran solutions in anaesthetized cats. Br. J. Pharmacol. 1981, 74:266.
54. Iwasaki K., Ajisaka K., Iwashita Y. Hemoglobin-inulin conjugate as an oxygen-carrying blood substitute. Biochem. Biophys. Res. Comm. 1983, 113:513-518.
55. Jesch F., Peters W., Hobbhahn J., et al. Oxygen-transporting fluids and oxygen delivery with hemodilution. Crit. Care Med. 1982, 10:270-274.
56. Jones R., Head C., Fujita T., et al. Structural studies of hemoglobin modified with dicarboxylic acid bis(methyl phosphate) crosslinking reagents. Biomat. Artif. Cells Artif. Organs 1989, 17(5):643.
57. Keipert P., Triner L. Catabolism and excretion of crosslinked hemoglobin. The Red Cell: Seventh Ann Arbor Conference 1989, 383-405. Alan R. Liss, New York. G. Brewer (Ed.).
58. Keipert P., Verosky M., Triner L. Metabolism, distribution, and excretion of HbXL: a nondissociating interdimerically crosslinked hemoglobin with exceptional oxygen offloading capability. Biomat. Artif. Cells Artif. Organs 1988, 16:643-645.
59. Keipert P., Aderiran A., Kwong S., Benesch R. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute. Transfusion 1989, 29:768-773.
60. Leonard M., Dellacherie E. Acylation of human hemoglobin with polyoxyethylene derivatives. Biochem. Biophys. Acta 1984, 791(2):219-225.
61. Lieberthal W., Fuhro R., Freedman J.E., et al. O-raffinose crosslinking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J. Pharmacol. Exper. Ther. 1999, 288(3):1278-1287.
62. Looker D., Abbott-Brown D., Cozart P., et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature 1992, 356:258-260.
63. MacDonald V., Winslow R. Oxygen delivery and myocardial function in rabbit hearts perfused with cell-free hemoglobin. J. Appl. Physiol. 1992, 72:476-483.
64. 2-terminal residues. Methods Enzymology 1981, 159-167. Academic Press, New York. 1976 edn. E. Antonini, L. Rossi-Bernardi, E. Chiancone (Eds.).
65. Manning J., Fantl W., Manning L., Ueno H. Carboxymethylated crosslinked hemoglobin A. Biomat. Artif. Cells Artif. Organs 1989, 17(5):639.
66. 0. Biopolymers 1989, 28:2071-2083.
67. Marini M., Moore G., Fishman R., et al. Reexamination of the polymerization of pyridoxylated hemoglobin with glutaraldehyde. Biopolymers 1990, 29:871-882.
68. Matheson B., Kwansa H.E., Rebel A., et al. Vascular response to infusions of a non extravasating hemoglobin polymer. J. Appl. Physiol. 2002, 93:1479-1486.
69. Matsushita M., Yabuki A., Malchesky P., et al. In vivo evaluation of a pyridoxalated-hemoglobin-polyoxyethylene conjugate. Biomat. Artif. Cells Artif. Organs 1988, 16(1-3):247-260.
70. Matsushita M., Yabuki A., Chen J., et al. Renal effects of pyridoxalated-hemoglobin-polyoxyethylene conjugate solution as a blood substitute in exchange transfusions. Am. Soc. Artif. Int. Organs Trans. 1988, 34(3):280-283.
71. McCarthy M.R., Vandegriff K.D., Winslow R.M. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys. Chem. 2001, 92(1-2):103-117.
72. McGarrity M., Nightingale K., Hsia J. ATP-hemoglobin: anomalous oxygen binding properties. J. Chromatog. Biomed. Appl. 1987, 415:136-142.
73. McPherson J., Sawamura S., Armstrong R. An examination of the biologic response to injectable glutaraldehyde crosslinked collagen implants. J. Biomed. Mater. Res. 1986, 20:93-107.
74. Mok W., Chen D., Mazur A. Crosslinked hemoglobins as potential plasma expanders. Fed. Proc. 1975, 34:1458-1460.
75. Moss G., Gould S., Sehgal L., et al. Hemoglobin solution-from tetramer to polymer. Biomat. Artif. Cells. Artif. Organs 1988, 16(1-3):57-69.
76. Rabiner S., Helbert J., Lopas H., Friedman L. Evaluation of stroma-free haemoglobin for use as a plasma expander. J. Exper. Med. 1967, 126:1127-1142.
77. Resta T., Walker B., Eichinger M., Doyle M. Rate of NO scavening alters effects of recombinant hemoglobin solutions on pulmonary vasoreactivity. J. Appl. Physiol. 2002, 93:1327-1336.
78. Rosen A., Sehgal L., Gould S., et al. Methodology to assess the oxygen concentration of red cells and stroma-free hemoglobin solutions. Crit. Care Med. 1986, 14(2):147-150.
79. San George R., Hoberman H. Reaction of acetaldehyde with hemoglobin. J. Biol. Chem. 1986, 261(15):6811-6821.
80. Savitsky J.P., Diczi J., Black J., Arnold J.D. A clinical safety trial of stroma-free hemoglobin. Clin. Pharmacol. Ther. 1978, 23(1):73-80.
81. Scannon P. Molecular modifications of hemoglobin. Crit. Care Med. 1982, 10:261-265.
82. Schmidt K. Polyvinylpyrrolidon-gebundenes Hämoglobin als ein Sauerstoff übertragender Blutersatzstoff. Klin. Wochenschr. 1979, 57:1169-1175.
83. Sehgal L., Rosen A., Gould S., et al. In vitro and in vivo characteristics of polymerized pyridoxylated hemoglobin solution. Fed. Proc. 1980, 39:718.
84. Sehgal L., Rosen A., Noud G., et al. Large-volume preparation of pyridoxalated hemoglobin with high P50. J. Surg. Res. 1981, 30(1):14-20.
85. Sehgal L., Gould S., Rosen A., et al. Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery 1984, 95(4):433-438.
86. Sloviter H., Mukherji B., Benesch R., et al. Persistence of intradimerically crosslinked hemoglobin in rat plasma. Fed. Proc. 1981, 42:652.
87. Snyder S., Welty E., Walder R., et al. HbXL99a: A hemoglobin derivative that is crosslinked between the subunits is useful as a blood substitute. Proc. Natl. Acad. Sci. USA 1987, 84:7280-7284.
88. Speer D., Chvapil M., Eslekson C., Ulreich J. Biologic effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials. J. Biomed. Mater. Res. 1980, 14:753-764.
89. Swanson M., Martin M., O'Donnell K., et al. Production of functional human hemoglobin in transgenic swine. Biotechnology 1992, 10(5):557-559.
90. Tam S., Blumenstein J., Wong J. Soluble dextran-hemoglobin complex as a potential blood substitute (plasma expander/oxygen binding/covalent coupling). Proc. Natl. Acad. Sci. USA 1976, 73(6):2128-2131.
91. Triner L., Benesch R., Benesch R., et al. The rate of plasma clearance of crosslinked and pyridoxylated hemoglobin in the rat. Physiologist 1983, 26:A69.
92. Tye R., Medina F., Bolin R., et al. Modification of hemoglobin-tetrameric stabilization. Progress in Clinical and Biological Research: Advances in Blood Substitute Research 1983, 41-49. Alan R. Liss, New York. R. Bolin, R. Geyer, G. Nemo (Eds.).
93. Vandegriff K., Medina F., Marini M., Winslow R. Equilibrium oxygen binding to human hemoglobin crosslinked between the alpha chains by bis(3,5-dibromosalicyl) fumarate. J. Biol. Chem. 1989, 264:17824-17833.
94. Vandegriff K.D., Malavalli A., Wooldridge J., et al. MP4, a new non-vasoactive polyethylene glycol-hemoglobin conjugate. Transfusion 2003, 43(4):509-516.
95. VanderPlas J., Rossen V.-V.A., Bleeker W., Bakker J. Effect of coupling of 2-nor-2-formylpyridoxal 5′-phosphate to stroma-free hemoglobin on oxygen affinity and tissue oxygen. Studies in the isolated perfused rat liver under conditions of normoxia and stagnant hypoxia. J. Lab. Clin. Med. 1986, 108:253-260.
96. VanderPlas J., Damm J., Bakker J. Preparation and physical characteristics of a hemoglobin solution modified by coupling to 2-nor-2-formylpyridoxal 5′-phosphate. Transfusion 1987, 27:425-430.
97. Walder J., Zaugg R., Walder R., et al. Diaspirins that crosslink B chains of hemoglobin: bis(3,5-dibromosalicyl) succinate and bis (3,5-dibromosalicyl) fumarate. Biochemistry 1979, 18:4265-4270.
98. Walder J., Walder R., Arnone A. Development of antisickling compounds that chemically modifty hemoglobin S specifically within the 2,3-diphosphoglycerate binding site. J. Mol. Biol. 1980, 141:195-216.
99. Walder J., Chatterjee R., Arnone A. Electrostatic effects within the central cavity of the hemoglobin tetramer. Fed. Proc. 1982, 41:651. (abstr. 2228).
100. Winslow R. Blood substitutes-current status. Transfusion 1989, 29(9):753-754.
101. Winslow R.M. αα-Crosslinked hemoglobin: was failure predicted by preclinical testing?. Vox Sang. 2000, 79:1-20.
102. Wong J. Rightshifted dextran-hemoglobin as blood substitute. Artif. Cells Blood Subst. Immob. Biotech. 1988, 16(1-3):237-245.
103. Wood L., Haney D., Patel J., et al. Structural specificities in acylation of hemoglobin and sickle hemoglobin by diaspirins. J. Biol. Chem. 1981, 256:7046-7052.
104. Xu X., Porter L., Wong J. Properties of oxidized inositoltetrakisphosphate-rightshifted hemoglobin and dextran-hemoglobin. Biomat. Artif. Cells Artif. Organs 1989, 17(5):645.
105. Zaugg R., King L., Klotz I. Acylation of hemoglobin by succinyldisalicy late, a potential cross-linking reagent. Biochem. Biophys. Res. Comm 1975, 64(4):1192-1198.